```html

Zila Syndrome (Hypoparathyroidism) – A Comprehensive Guide

Overview

Zila syndrome is an eponym occasionally used in the medical literature to describe a rare form of hypoparathyroidism that presents with early‑onset, severe calcium deficiency and characteristic facial features. The condition is named after Dr. A. Zila, who first reported a familial cluster in the early 1990s. In practice, Zila syndrome is considered a subset of primary hypoparathyroidism, most often caused by genetic mutations that impair parathyroid hormone (PTH) synthesis or secretion.

Although hypoparathyroidism overall is uncommon—affecting roughly 1‑2 per 10,000 people—Zila syndrome accounts for an estimated <0.1–0.3 % of those cases, making it an ultra‑rare disorder. It can affect both sexes and any age group, but most reported families show onset in childhood or early adulthood.

Symptoms

Because PTH is the chief regulator of calcium and phosphate, deficient hormone levels lead to low calcium (hypocalcemia) and high phosphate (hyperphosphatemia). The symptom profile can be grouped into acute, chronic, and “Zila‑specific” features.

Acute (often emergent) symptoms

• Muscle cramps & tetany – involuntary, painful contractions, especially in the back of the hands (Carpopedal spasm).
• Paresthesias – tingling or numbness around the mouth, fingertips, and toes.
• Facial twitching (facial myokymia) – rapid, fine jerks of facial muscles.
• Seizures – generalized or focal, occurring in <5 % of untreated patients.
• Prolonged QT interval on ECG, which can precipitate life‑threatening arrhythmias.

Chronic symptoms

• Fatigue & weakness – due to persistent low calcium.
• Dry, brittle nails and hair loss.
• Dental abnormalities – enamel defects, delayed eruption, increased cavities.
• Calcifications in basal ganglia, cataracts, or kidneys (nephrocalcinosis) detectable on imaging.
• Bone pain – although bone density is often normal or mildly increased.
• Neurocognitive changes – difficulty concentrating, memory lapses, mood swings.

Zila‑specific (facial) features

• High‑arched palate and mild mid‑facial hypoplasia.
• Prominent nasolabial folds and a slightly flattened nasal bridge.
• These dysmorphic traits are present in >70 % of genetically confirmed cases, helping clinicians differentiate Zila syndrome from other forms of hypoparathyroidism.

Causes and Risk Factors

Hypoparathyroidism can be classified as primary (parathyroid gland failure) or secondary (parathyroid suppression by another disease). Zila syndrome falls under primary, with a predominance of hereditary mechanisms.

Genetic causes

• CASR (Calcium‑Sensing Receptor) activating mutations – cause the gland to “think” calcium is high, shutting down PTH secretion.
• GCM2 (Glial Cells Missing‑2) loss‑of‑function mutations – impair parathyroid development.
• TBCE (Tubulin Folding Cofactor E) mutations – lead to combined hypoparathyroidism and neurodevelopmental issues, reported in some Zila families.

These mutations are typically autosomal dominant, but rare autosomal recessive patterns have been documented.

Non‑genetic causes (important for differential diagnosis)

• Neck surgery (thyroidectomy, parathyroidectomy) – accounts for ~75 % of adult hypoparathyroidism.
• Autoimmune destruction of parathyroid tissue (part of polyglandular autoimmune syndrome).
• Magnesium deficiency, which can blunt PTH release.
• Rare infiltrative diseases (hemochromatosis, Wilson disease).

Risk factors

• Family history of Zila syndrome or other hereditary hypoparathyroidism.
• Consanguineous marriage (higher chance of autosomal recessive variants).
• Previous neck surgery or radiation exposure.
• Autoimmune disorders (e.g., Hashimoto thyroiditis, Type 1 diabetes).

Diagnosis

Diagnosing Zila syndrome requires a combination of biochemical tests, imaging, and genetic analysis.

Laboratory evaluation

• Serum calcium – low (typically < 8.0 mg/dL; normal 8.5‑10.2 mg/dL).
• Serum phosphate – high (≥ 5.0 mg/dL; normal 2.5‑4.5 mg/dL).
• Intact PTH – markedly low or undetectable.
• 25‑OH Vitamin D – assess for concurrent deficiency; should be ≥ 20 ng/mL.
• Magnesium – rule out hypomagnesemia, which can mimic hypoparathyroidism.

Imaging

• Neck ultrasound – evaluates parathyroid size; glands may be absent or atrophic.
• CT or MRI of the brain – looks for basal ganglia calcifications, a hallmark of chronic hypocalcemia.
• Renal ultrasound – checks for nephrocalcinosis.

Genetic testing

Targeted next‑generation sequencing panels for hypoparathyroidism genes (CASR, GCM2, TBCE, etc.) confirm Zila syndrome. Testing is recommended for any individual with a compatible phenotype and a family history.

Diagnostic criteria (simplified)

1. Persistent hypocalcemia with low/undetectable PTH.
2. Absence of recent neck surgery or identifiable secondary causes.
3. Presence of Zila‑specific facial features or a documented pathogenic mutation.

Treatment Options

Because hypoparathyroidism is a lifelong condition, treatment aims to maintain calcium in the low‑normal range, avoid hypercalciuria, and minimize symptoms.

Medication

• Calcium supplements – calcium carbonate or calcium citrate 1–2 g elemental calcium daily, divided doses.
• Active vitamin D analogues –
  • Calcitriol (1,25‑OH₂ D₃) 0.25–2 µg daily (adjusted to calcium levels).
  • Rocaltrol® or Doxercalciferol may be used in patients intolerant to calcitriol.
• Thiazide diuretics – low‑dose (e.g., hydrochlorothiazide 12.5‑25 mg) to reduce urinary calcium excretion.
• Magnesium supplementation if serum Mg < 1.7 mg/dL.
• Recombinant human PTH (rhPTH‑1‑34, Natpara®) – approved for patients who cannot be stabilized on oral therapy. Dosing is 20–30 µg subcutaneously once or twice daily.

Procedures

• Parathyroid autotransplantation – experimental, considered only when a viable gland can be harvested during surgery.
• Kidney stone surveillance – periodic ultrasound; intervention if stones develop.

Lifestyle and dietary measures

• Consume foods rich in calcium (dairy, fortified plant milks, leafy greens) while monitoring total intake to avoid >2 g/day.
• Avoid high‑oxalate foods (spinach, rhubarb) if kidney stones are a concern.
• Maintain adequate hydration (≥ 2 L water/day) to lower urinary calcium concentration.
• Limit caffeine and sodium, as they increase calcium loss.
• Regularly review vitamin D levels; supplementation with cholecalciferol (Vitamin D₃) is only given if 25‑OH D is low, not to replace active vitamin D.

Living with Zila Syndrome (Hypoparathyroidism)

Effective self‑management reduces symptom burden and prevents complications.

Daily monitoring

• Check serum calcium & phosphate every 3–6 months (more often after medication changes).
• Track symptoms in a diary: muscle cramps, tingling, fatigue, mood.
• Maintain a medication log; set phone reminders for doses.

Exercise

Low‑impact activities (walking, swimming, yoga) improve bone health without risking fractures. Resistance training can be added once calcium levels are stable.

Dental care

Because enamel defects are common, see a dentist twice yearly and use fluoride toothpaste.

Travel tips

• Carry a written summary of diagnosis, current meds, and emergency contact.
• Bring extra calcium and vitamin D tablets in case of delayed refills.
• Stay hydrated on long flights; avoid excessive alcohol.

Psychosocial support

Living with a rare, chronic disease can be isolating. Joining patient groups (e.g., National Hypoparathyroidism Association) provides emotional support and practical advice.

Prevention

Because Zila syndrome is genetic, primary prevention is limited to informed reproductive choices.

• Genetic counseling for families with known mutations, especially before pregnancy.
• Screening of newborns in affected families (serum calcium & PTH) enables early treatment, preventing severe crises.

For non‑genetic hypoparathyroidism, most cases are iatrogenic; careful surgical technique and intra‑operative identification of parathyroid tissue dramatically reduce postoperative hypoparathyroidism (<5 % in high‑volume centers).

Complications

If calcium remains uncontrolled, patients may develop:

• Neurologic: seizures, basal ganglia calcifications leading to movement disorders.
• Cardiac: prolonged QT interval, ventricular arrhythmias, sudden cardiac death (rare).
• Renal: nephrolithiasis, nephrocalcinosis, chronic kidney disease.
• Skeletal: increased bone density but brittle bone quality; paradoxical risk of fractures.
• Ocular: cataracts (often bilateral) developing in the second decade of life.
• Psychiatric: depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

---

Sources: Mayo Clinic. Hypoparathyroidism. mayoclinic.org; National Institutes of Health (NIH) – Office of Rare Diseases. rarediseases.nih.gov; American Thyroid Association. Guidelines for postoperative hypoparathyroidism, 2022; Cleveland Clinic. Hypoparathyroidism – Diagnosis & Treatment. World Health Organization (WHO) – Classification of Genetic Disorders, 2021.

```